PURPOSE To provide recommendations on the use of poly (ADP-ribose) polymerase
inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer …

Background In recurrent ovarian cancer, poly (ADP-ribose) polymerase (PARP)-inhibiting
agents have transformed the treatment of platinum-sensitive disease. New data support use …

Opinion statement Poly-ADP-ribose polymerase inhibitors (PARPi) are a class of anti-cancer
drugs that target DNA repair pathways and have shown promising efficacy in patients with …

Background: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery
and platinum doublet chemotherapy, is associated with high risk of relapse and poor …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the
ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive …

Background Slow progress in improving the outcome of ovarian cancer with chemotherapy
over the last decade has stimulated research into molecularly targeted therapy. Poly (ADP …

Background Poly-ADP-ribose polymerase (PARP) inhibitors have emerged as a novel class
of therapeutics for ovarian cancer (OC); however, PARP inhibitors present a class effect …

For several decades, the systemic treatment of ovarian cancer has involved chemotherapy,
with the relatively recent addition of antiangiogenic strategies given with chemotherapy and …

Inhibitors of poly (ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …

Background Despite standard treatment for epithelial ovarian cancer (EOC), that involves
cytoreductive surgery followed by platinum-based chemotherapy, and initial high response …